摘要
目的:探讨胸腺肽联合苦参碱治疗慢性乙型肝炎的临床疗效。方法:选取128例慢性乙型肝炎患者,随机分为观察组和对照组,观察组在常规护肝治疗同时应用胸腺肽联合苦参碱治疗,对照组单纯给予胸腺肽治疗,观察两组治疗前后临床症状、肝功能、HBV标志物变化情况。结果:在临床症状改善方面,两组差异不大,在肝功能改善、HBeAg阴转率、HBeAb阳转率、HBVDNA阴转或下降10^3copies·ml^-1以上发生率方面,观察组与对照比较,有明显统计学意义(p<0.05)。结论:胸腺肽联合苦参碱是慢性乙肝病人较好选择,值得在临床试用推广。
Objective：Of combined matrine treatment of chronic hepatitis B with thymosin clinical efficacy.Methods：128 cases of chronic hepatitis B were randomly divided into two groups and the control group,the observation group in the conventional application of thymosin Liver treatment combined matrine treatment while the control group were given thymosin,clinical symptoms were observed before and after treatment,liver function,HBV markers changes.Results：Clinical symptoms improved in the two groups is insignificant,improvement in liver function,HBeAg negative conversion rate,HBeAb seroconversion rate,HBVDNA conversion or down 10^3copies·ml^-1 above the rate,the observation group and comparisons,there are clear statistical significance （p0.05）.Conclusion：Thymosin combined matrine is a good choice for chronic hepatitis B patients,in clinical trials to promote.
出处
《医学信息（中旬刊）》
2011年第9期4885-4886,共2页
Medical Information Operations Sciences Fascicule
